EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Association of CDKN2A /B Homozygous Deletion and Extent of Resection With Survival of Patients With WHO CNS5 Grade 4 Astrocytoma

Jiawei Cai, Guanglin Zhu, Qiu He, Chen Luo, Lingyun Zhuo, Xingfu Wang, Yiming Chen, Xiaoyong Chen, Wendong You, Jiaheng Xu, Yuanxiang Lin, Dezhi Kang iD und 2 weitere

Annals of Clinical and Translational Neurology · 2026

DOI: 10.1002/acn3.70310 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Clinical and Translational Neurology, 2026. Verfasst von Jiawei Cai und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Neurosurgery Research Institute, the First Affiliated Hospital of Fujian Medical University, Fuzhou, China. Hauptthemen laut MEDLINE: Astrocytoma, Brain Neoplasms, Cyclin-Dependent Kinase Inhibitor p16, Cyclin-Dependent Kinase Inhibitor p15. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Neurosurgery Department High-Level Innovation Construction Project for Major Research at the Neurological Diseases Center, Natural Science Foundation of Fujian Province, Joint Funds for the Innovation of Science and Technology, Fujian Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

WHO grade 4 astrocytomas are associated with poor prognosis, and their prognostic factors remain controversial. This study aimed to identify the prognostic factors and develop a management algorithm for these patients.

Methods

This study retrospectively included 151 CNS5 adult grade 4 astrocytomas from two medical centers. The tumors were classified as histologic grade 2/3 astrocytomas with CDKN2A/B homozygous deletion (molecular grade 4 astrocytoma, MA4), histologic grade 4 astrocytomas with CDKN2A/B homozygous deletion (molecular and histologic grade 4 astrocytoma, MHA4), and histologic grade 4 astrocytomas without CDKN2A/B homozygous deletion (histologic grade 4 astrocytoma, HA4). Prognostic factors were identified and incorporated into recursive partitioning analysis (RPA) for survival risk stratification.

Results

Histologic grade 4 astrocytomas with CDKN2A/B homozygous deletion, postoperative tumor volume (TV), and chemoradiotherapy were associated with patient survival. RPA identified three groups with distinct prognoses ( p = 0.001). Group 1 had a median overall survival (OS) of 77.8 months, consisting of MA4 and HA4 with postoperative TV on FLAIR ≤ 28.5 mL. Group 2 had a median OS of 32.2 months, including MA4 and HA4 with postoperative TV on FLAIR > 28.5 mL receiving chemoradiotherapy, or MHA4 with postoperative TV on FLAIR ≤ 28.5 mL. Group 3 had a median OS of 14.9 months, including MA4 and HA4 with postoperative TV on FLAIR > 28.5 mL without chemoradiotherapy, or MHA4 with postoperative TV on FLAIR > 28.5 mL receiving chemoradiotherapy.

Conclusion

Histologic grade 4 astrocytomas with CDKN2A/B homozygous deletion confer the worst survival. Maximal or complete resection, as assessed on FLAIR images, is critical to improving outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AstrocytomaBrain NeoplasmsCyclin-Dependent Kinase Inhibitor p16Cyclin-Dependent Kinase Inhibitor p15HumansFemaleMaleMiddle AgedAdultRetrospective StudiesNeoplasm GradingGene DeletionHomozygotePrognosisAgedYoung Adult

Stichwörter der Autor:innen

CDKN2A/Bextent of resectiongrade 4 astrocytomamanagement algorithmprognosis

Substanzen

Cyclin-Dependent Kinase Inhibitor p16Cyclin-Dependent Kinase Inhibitor p15CDKN2B protein, humanCDKN2A protein, human

Autor:innen und Institutionen

  • Department of Neurosurgery, Neurosurgery Research Institute, the First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
  • Department of Neurosurgery, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
  • Department of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China.
  • School of Medical Technology and Engineering, Fujian Medical University, Fuzhou, China.

ORCID-Profile: Dezhi Kang, Zanyi Wu

Förderung

  • Neurosurgery Department High-Level Innovation Construction Project for Major Research at the Neurological Diseases Center
  • Natural Science Foundation of Fujian Province
  • Joint Funds for the Innovation of Science and Technology, Fujian Province

Zitieren

APA

Cai, J., Zhu, G., He, Q., Luo, C., Zhuo, L., Wang, X., Chen, Y., Chen, X., You, W., Xu, J., Lin, Y., Kang, D., Wu, S., & Wu, Z. (2026). Association of CDKN2A /B Homozygous Deletion and Extent of Resection With Survival of Patients With WHO CNS5 Grade 4 Astrocytoma. Annals of Clinical and Translational Neurology. https://doi.org/10.1002/acn3.70310

Vancouver

Cai J, Zhu G, He Q, Luo C, Zhuo L, Wang X, et al. Association of CDKN2A /B Homozygous Deletion and Extent of Resection With Survival of Patients With WHO CNS5 Grade 4 Astrocytoma. Annals of Clinical and Translational Neurology. 2026. doi:10.1002/acn3.70310

BibTeX
@article{Cai2026,
  author = {Cai, Jiawei and Zhu, Guanglin and He, Qiu and Luo, Chen and Zhuo, Lingyun and Wang, Xingfu and Chen, Yiming and Chen, Xiaoyong and You, Wendong and Xu, Jiaheng and Lin, Yuanxiang and Kang, Dezhi and Wu, Shuai and Wu, Zanyi},
  title = {Association of CDKN2A /B Homozygous Deletion and Extent of Resection With Survival of Patients With WHO CNS5 Grade 4 Astrocytoma},
  journal = {Annals of Clinical and Translational Neurology},
  year = {2026},
  doi = {10.1002/acn3.70310}
}
Kostenlos starten →